Market News AIOpen the app

Viking Therapeutics Stock Dips Despite Positive VK2735 Data: What’s Going On?

TrialRead the original at Benzinga
Good for VKTX

Viking's exploratory analysis found 74% of treated participants improved by at least 1 body-mass category, versus 15% on placebo. This adds encouraging evidence, though it adds detail to earlier results and the larger 78-week study remains the key test.

VKTX · Viking Therapeutics Inc

AI read · Good for VKTX

The AI's read

These findings suggest VK2735 may improve health measures beyond body weight. The analysis is exploratory, and the larger study runs for 78 weeks. That leaves important questions unanswered, but the patient results still support Viking's drug program.

Get alerts for VKTX

Follow Viking Therapeutics Inc (VKTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VKTX
Free on the App Store and Google Play, or on the web.